281 related articles for article (PubMed ID: 20660190)
1. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.
Bandaranayake RM; Kolli M; King NM; Nalivaika EA; Heroux A; Kakizawa J; Sugiura W; Schiffer CA
J Virol; 2010 Oct; 84(19):9995-10003. PubMed ID: 20660190
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.
Ode H; Matsuyama S; Hata M; Hoshino T; Kakizawa J; Sugiura W
J Med Chem; 2007 Apr; 50(8):1768-77. PubMed ID: 17367119
[TBL] [Abstract][Full Text] [Related]
3. Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.
Liu X; Xiu Z; Hao C
J Comput Aided Mol Des; 2009 May; 23(5):261-72. PubMed ID: 19219633
[TBL] [Abstract][Full Text] [Related]
4. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
[TBL] [Abstract][Full Text] [Related]
5. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
6. Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.
Bihani SC; Das A; Prashar V; Ferrer JL; Hosur MV
Biochem Biophys Res Commun; 2009 Nov; 389(2):295-300. PubMed ID: 19720046
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 protease-substrate coevolution in nelfinavir resistance.
Kolli M; Ozen A; Kurt-Yilmaz N; Schiffer CA
J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428
[TBL] [Abstract][Full Text] [Related]
9. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.
Ode H; Ota M; Neya S; Hata M; Sugiura W; Hoshino T
J Phys Chem B; 2005 Jan; 109(1):565-74. PubMed ID: 16851048
[TBL] [Abstract][Full Text] [Related]
10. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
Velazquez-Campoy A; Vega S; Freire E
Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
[TBL] [Abstract][Full Text] [Related]
11. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
Ntemgwa M; Brenner BG; Oliveira M; Moisi D; Wainberg MA
Antimicrob Agents Chemother; 2007 Feb; 51(2):604-10. PubMed ID: 17116674
[TBL] [Abstract][Full Text] [Related]
12. Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.
Vasavi CS; Tamizhselvi R; Munusami P
J Mol Graph Model; 2017 Aug; 75():390-402. PubMed ID: 28645089
[TBL] [Abstract][Full Text] [Related]
13. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
Prashar V; Bihani SC; Ferrer JL; Hosur MV
Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
[TBL] [Abstract][Full Text] [Related]
14. Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.
Mittal S; Bandaranayake RM; King NM; Prabu-Jeyabalan M; Nalam MN; Nalivaika EA; Yilmaz NK; Schiffer CA
J Virol; 2013 Apr; 87(8):4176-84. PubMed ID: 23365446
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.
Sasková KG; Kozísek M; Rezácová P; Brynda J; Yashina T; Kagan RM; Konvalinka J
J Virol; 2009 Sep; 83(17):8810-8. PubMed ID: 19535439
[TBL] [Abstract][Full Text] [Related]
16. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes.
Mahalingam B; Louis JM; Hung J; Harrison RW; Weber IT
Proteins; 2001 Jun; 43(4):455-64. PubMed ID: 11340661
[TBL] [Abstract][Full Text] [Related]
17. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease.
Ragland DA; Nalivaika EA; Nalam MN; Prachanronarong KL; Cao H; Bandaranayake RM; Cai Y; Kurt-Yilmaz N; Schiffer CA
J Am Chem Soc; 2014 Aug; 136(34):11956-63. PubMed ID: 25091085
[TBL] [Abstract][Full Text] [Related]
19. Structures of darunavir-resistant HIV-1 protease mutant reveal atypical binding of darunavir to wide open flaps.
Zhang Y; Chang YC; Louis JM; Wang YF; Harrison RW; Weber IT
ACS Chem Biol; 2014 Jun; 9(6):1351-8. PubMed ID: 24738918
[TBL] [Abstract][Full Text] [Related]
20. Decomposing the energetic impact of drug-resistant mutations: the example of HIV-1 protease-DRV binding.
Cai Y; Schiffer C
Methods Mol Biol; 2012; 819():551-60. PubMed ID: 22183557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]